Kelsey S M, Hider R C, Bloor J R, Blake D R, Gutteridge C N, Newland A C
Department of Haematology, London Hospital, U.K.
J Clin Pharm Ther. 1991 Apr;16(2):117-22. doi: 10.1111/j.1365-2710.1991.tb00292.x.
Ferric maltol is a novel ferric iron compound with potential use as an oral therapy for iron deficiency anaemia. Using a single, low dose iron absorption test we compared absorption of ferric maltol with absorption of ferrous sulphate in 21 iron deficient subjects. Absorption of 10 mg of ferric maltol as either aqueous solution or a single tablet compared favourably with that of an equivalent dose of ferrous sulphate. At a higher, more therapeutic dose of 60 mg elemental iron as tablets, absorption of ferric maltol appeared to be both more rapid and total absorption greater, than that seen with ferrous sulphate. We conclude that iron from ferric maltol, both at low dose and higher, more therapeutic doses, is at least as well absorbed as from ferrous sulphate. Ferric maltol is the first ferric iron formulation to be absorbed to a degree equivalent to that of ferrous iron salts and may represent a viable form of administration for ferric iron in the treatment of iron deficiency anaemia.
麦芽酚铁是一种新型的铁化合物,具有作为缺铁性贫血口服治疗药物的潜在用途。我们采用单次低剂量铁吸收试验,比较了21名缺铁受试者对麦芽酚铁和硫酸亚铁的吸收情况。10毫克麦芽酚铁水溶液或单片制剂的吸收情况与等量硫酸亚铁相比具有优势。在更高的、更具治疗效果的60毫克元素铁片剂剂量下,麦芽酚铁的吸收似乎更快,总吸收量也比硫酸亚铁更高。我们得出结论,低剂量和高剂量(更具治疗效果)的麦芽酚铁中的铁,其吸收效果至少与硫酸亚铁一样好。麦芽酚铁是第一种吸收程度与亚铁盐相当的三价铁制剂,可能是治疗缺铁性贫血时三价铁的一种可行给药形式。